PO-347 sONE, a novel tumour suppressor lncRNA, with diminished expression level in young triple negative breast cancer (TNBC) patients with lymphnode metastasis and large tumour size

The BIRC (baculoviral IAP repeat-containing; BIRC) family genes encode for Inhibitor of Apoptosis (IAP) proteins. The dysregulation of the expression levels of the genes in question in cancer tissue as compared to normal tissue suggests that the apoptosis process in cancer cells was disturbed, which may be associated with the development and chemoresistance of triple negative breast cancer (TNBC). In our study, we determined the expression level of eight genes from the BIRC family using the Real-Time PCR method in patients with TNBC and compared the obtained results with clinical data. Additionally, using bioinformatics tools (Ualcan and The Breast Cancer Gene-Expression Miner v4.5 (bc-GenExMiner v4.5)), we compared our data with the data in the Cancer Genome Atlas (TCGA) database. We observed diverse expression pattern among the studied genes in breast cancer tissue. Comparing the expression level of the studied genes with the clinical data, we found that in patients diagnosed with breast cancer under the age of 50, the expression levels of all studied genes were higher compared to patients diagnosed after the age of 50. We observed that in patients with invasion of neoplastic cells into lymphatic vessels and fat tissue, the expression levels of BIRC family genes were lower compared to patients in whom these features were not noted. Statistically significant differences in gene expression were also noted in patients classified into three groups depending on the basis of the Scarff-Bloom and Richardson (SBR) Grading System.

Download Full-text

ROLE OF TUMOUR SUPPRESSOR GENE P53 IN TRIPLE NEGATIVE BREAST CANCER

International Journal of Anatomy and Research ◽

10.16965/ijar.2017.402 ◽

2017 ◽

Vol 5 (4.2) ◽

pp. 4585-4589

Author(s):

Priya S Patil ◽

◽

Jaydeep N Pol ◽

Ashalata D Patil ◽

◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Suppressor Gene ◽

Tumour Suppressor Gene ◽

Tumour Suppressor

Download Full-text

Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer

BMC Cancer ◽

10.1186/1471-2407-14-51 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 50

Author(s):

Kelly A Avery-Kiejda ◽

Stephen G Braye ◽

Andrea Mathe ◽

John F Forbes ◽

Rodney J Scott

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Triple Negative Breast Cancer ◽

Lymph Node Metastases ◽

Triple Negative ◽

Tumour Suppressor ◽

Node Metastases

Download Full-text

Characterization of ceRNA network to reveal potential prognostic biomarkers in triple-negative breast cancer

PeerJ ◽

10.7717/peerj.7522 ◽

2019 ◽

Vol 7 ◽

pp. e7522 ◽

Cited By ~ 6

Author(s):

Xiang Song ◽

Chao Zhang ◽

Zhaoyun Liu ◽

Qi Liu ◽

Kewen He ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Quantitative Polymerase Chain Reaction ◽

The Cancer Genome Atlas ◽

Expression Level ◽

Cerna Network ◽

Kaplan Meier ◽

Cancer Genome Atlas ◽

Non Coding Rnas

Triple-negative breast cancer (TNBC) is a particular subtype of breast malignant tumor with poorer prognosis than other molecular subtypes. Previous studies have demonstrated that some abnormal expression of non-coding RNAs including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) were closely related to tumor cell proliferation, apoptosis, invasion, migration and drug sensitivity. However, the role of non-coding RNAs in the pathogenesis of TNBC is still unclear. In order to characterize the molecular mechanism of non-coding RNAs in TNBC, we downloaded RNA data and miRNA data from the cancer genome atlas database. We successfully identified 686 message RNAs (mRNAs), 26 miRNAs and 50 lncRNAs as key molecules for high risk of TNBC. Then, we hypothesized that the lncRNA–miRNA–mRNA regulatory axis positively correlates with TNBC and constructed a competitive endogenous RNA (ceRNA) network of TNBC. Our series of analyses has shown that five molecules (TERT, TRIML2, PHBP4, mir-1-3p, mir-133a-3p) were significantly associated with the prognosis of TNBC, and there is a prognostic ceRNA sub-network between those molecules. We mapped the Kaplan–Meier curve of RNA on the sub-network and also suggested that the expression level of the selected RNA is related to the survival rate of breast cancer. Reverse transcription-quantitative polymerase chain reaction showed that the expression level of TRIML2 in TNBC cells was higher than normal. In general, our findings have implications for predicting metastasis, predicting prognosis and discovering new therapeutic targets for TNBC.

Download Full-text

Triple negative breast cancer in a South African urban breast care centre.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e13067 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e13067-e13067

Author(s):

Leanne Prodehl ◽

Carol Benn

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

South African ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Tumour Size ◽

Pathological Response ◽

Advanced Stage ◽

Complete Pathological Response ◽

Breast Care

e13067 Background: Triple negative breast cancer (TNBC) is associated with advanced stage at presentation, aggressive tumour biology and poor outcomes. There is no published data for South Africa. Methods: A retrospective file review of TNBC cases at the Milpark Breast Care Unit in Johannesburg, South Africa, data were collected on presentation, treatment and outcomes. A prospective file review and telephonic interview were done for further follow up. Results: There were 196 patients with TNBC identified out of 1407 patients (13.9%), 135 patients were analysed. Stage at presentation was IIa and IIb in approximately half (46.7%) of the patients and IIIa, IIIb and IV in a third (31.8%). Patients presented with large tumours -71.8% were T2 to T4; and lymph node positive disease (55.6%). The majority of patients had high-grade, poorly differentiated tumours. The challenges when treating TNBC were reflected in the use of multimodality therapy; 92.2% of patients had chemotherapy, as neoadjuvant (59.3%), adjuvant or both. There were 93 (68.9%) patients treated with adjuvant radiation therapy. If neoadjuvant chemotherapy was given 91.2% had a response. Recurrences occurred in 33 patients, with a 5-year disease free survival of 72.5%, and preponderance to visceral metastases (45.2%). Recurrences occurred early, the median was 23.1 months and all had occurred within eight years. Younger patients (HR 1.58), tumour size and lymph node positivity (HR 4.42) were associated with increased risk of recurrence, but only lymph node positivity was significant (HR 4.42). Complete pathological response to neoadjuvant chemotherapy was associated with fewer recurrences if no tumour was found in either the breast or the lymph nodes (HR 0.33). The 5-year overall survival was 76.4%. There was no significant difference in survival for age, node status, nuclear grade, or complete pathological response, only tumour size at presentation was significantly associated. Conclusions: The prevalence of triple negative breast cancer in a South African breast care unit was similar to some European studies but less than studies in West and East Africa. Patients presented at an advanced stage and had poorer outcomes than luminal breast cancers.

Download Full-text

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis

BioMed Research International ◽

10.1155/2015/357485 ◽

2015 ◽

Vol 2015 ◽

pp. 1-12 ◽

Cited By ~ 4

Author(s):

Li Zhang ◽

Cheng Fang ◽

Xianqun Xu ◽

Anling Li ◽

Qing Cai ◽

...

Keyword(s):

Breast Cancer ◽

Androgen Receptor ◽

Targeted Therapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Meta Analysis ◽

Brca1 Mutation ◽

Expression Level ◽

Breast Cancer Susceptibility Gene ◽

Egfr Expression

Objective. More and more evidences demonstrate that androgen receptor (AR), epidermal growth factor receptor (EGFR), and breast cancer susceptibility gene 1 (BRCA1) have unique clinical implications for targeted therapy or prognosis in triple-negative breast cancer (TNBC). Therefore, we conducted a meta-analysis to summarize the possible associations.Methods. We retrieved published articles about AR, EGFR, and BRCA1 in TNBC from PubMed and EMBASE. The analysis was performed with Rev-Man 5.2 software.Results. A total of 38 articles were eligible for the meta-analysis. Our study showed that the expression level of EGFR (OR=6.88,P<0.00001) and the prevalence of BRCA1 mutation (RR=5.26,P<0.00001) were higher in TNBC than non-TNBC. In contrast, the expression level of AR was lower in TNBC than non-TNBC (OR=0.07,P<0.00001). In the subgroup related to EGFR expression, the level of EGFR expression was significantly increased in Asians (OR=9.60) compared with Caucasians (OR=5.53) for TNBC patients. Additionally, the prevalence of BRCA1 mutation in Asians (RR=5.43,P<0.00001) was higher than that in Caucasians (RR=5.16,P<0.00001).Conclusions. The distinct expression of AR and EGFR and the prevalence of BRCA1 mutation indicated that AR, EGFR, and BRCA1 might be unique biomarkers for targeted therapy and prognosis in TNBC.

Download Full-text

Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience

Sultan Qaboos University Medical Journal [SQUMJ] ◽

10.18295/squmj.2019.19.03.006 ◽

2019 ◽

Vol 19 (3) ◽

pp. 209

Author(s):

Shiyam Kumar ◽

Muhammad Furrukh ◽

Khalid Al-Baimani ◽

Adil Al-Ajmi ◽

Ikram A. Burney ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Tumour Size ◽

Patient Outcome Assessment ◽

University Hospital ◽

Stage Iii ◽

Sultan Qaboos University

Objectives: Triple-negative breast cancer (TNBC) is one of the most aggressive and heterogeneous variants of breast cancer. However, little is known regarding the prevalence and outcome of this entity in the Middle East. This study aimed to evaluate the outcomes of TNBC patients at a university hospital in Oman. Methods: This retrospective study took place at the Sultan Qaboos University Hospital, Muscat, Oman, in May 2017. All patients diagnosed with non-metastatic TNBC between December 2000 and December 2015 were included. The patients’ electronic medical records were reviewed to identify their clinical and pathological characteristics as well as survival outcomes. Results: A total of 79 patients were diagnosed with non-metastatic TNBC during the study period. The median age was 46 years, with approximately one-third of patients (31.6%) under 40 years of age. Almost half had an advanced tumour size (49.4%) or node-positive disease (48.1%) at presentation and only 16.6% demonstrated a complete pathological response (pCR) to neoadjuvant chemotherapy. The median survival for all patients was not reached within the study period; however, the median overall survival for stage III patients was 44.6 months. The five-year overall survival for all patients was 64%, increasing to 100% and 72% for patients with stage I and II, respectively, and dropping to 47% for those with stage III disease. Conclusion: The findings of this study indicate that the majority of women with TNBC in Oman present at an advanced stage; moreover, such women have low rates of pCR to neoadjuvant chemotherapy and poor five-year survival.Keywords: Breast Cancer; Triple-Negative Breast Cancer; Neoadjuvant Therapy; Survival; Patient Outcome Assessment; Oman.

Download Full-text

Prognostic Factors and Survival Analysis of Patients with Triple Negative Breast Cancer - A Retrospective Study from a Tertiary Care Teaching Hospital in Kerala

Journal of Evidence Based Medicine and Healthcare ◽

10.18410/jebmh/2021/246 ◽

2021 ◽

Vol 8 (18) ◽

pp. 1287-1292

Author(s):

Binitha Tresa Thomas ◽

Preeya Vasanthakumary ◽

Ancy Joseph

Keyword(s):

Breast Cancer ◽

Multivariate Analysis ◽

Prognostic Factors ◽

Retrospective Study ◽

Growth Factor ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Tumour Size ◽

Univariate Analysis ◽

Nodal Density

BACKGROUND Breast cancer is now the most common cancer in Indian women, having recently surpassed cervical cancer in incidence. Triple negative breast cancer (TNBC), which accounts for 15 % of all the breast cancers is an aggressive type seen in younger women with early signs of metastasis, has a poor prognosis due to systemic recurrence and its refractoriness to conventional adjuvant therapy. The purpose of this study was to look into the various prognostic factors associated with 5 years disease-free survival (DFS) and overall survival (OS) in TNBC. METHODS This retrospective study included 67 patients with complete treatment and followup (median 57 months) presented and treated in the Department of Radiotherapy, Kottayam, between January 2011 and December 2012. The Kaplan-Meier approach was used to analyse survival. Using the log-rank test, univariate analysis of prognostic factors was completed. Using the Cox regression process, multivariate analysis was performed on IBM SPSS version 20. RESULTS The average age was 51.36 ± 11.393 (median, 51.36 years; range 30.0 – 80.0 years), with a median of 50 months, the five-year OS was 65.7 % and DFS was found to be 59.7 % with a median of 45 months, suggesting aggressive nature and poor TNBC survival. Univariate analysis of prognostic factor, clinical stage (cN) and positive nodes (pN) status, clinical tumour size, lympho-vascular invasion (LVI), grade, and nodal density were found to have a significant impact on DFS. Except tumour grade and LVI all were found to be associated with OS. Multivariate analysis, clinical tumour size and pathological nodal status had a significant impact on OS and DFS. CONCLUSIONS TNBC is an aggressive subtype of breast cancer in younger patients with a high risk of metastasis to visceral organs with inherent molecular subtypes and immunological heterogeneity. For treatment of TNBC, targeted estimated glomerular filtration rate (EGFR), fibroblast growth factor receptor 2 (FGFR2), vascular endothelial growth factor (VEGF), and mechanistic target of rapamycin (mTOR) receptor based initial treatment setting will improve the outcome dramatically and will fill the unmet clinical needs. KEYWORDS TNBC, Recurrence, OS, DFS, Nodal Density

Download Full-text

Breast cancer incidence: Decreasing trend in large tumours in women aged 50–74

Journal of Medical Screening ◽

10.1177/0969141316672894 ◽

2016 ◽

Vol 24 (4) ◽

pp. 189-194 ◽

Cited By ~ 3

Author(s):

Florence Molinié ◽

Solenne Delacour-Billon ◽

Brigitte Tretarre ◽

Patricia Delafosse ◽

Brigitte Seradour ◽

...

Keyword(s):

Breast Cancer ◽

Incidence Rate ◽

Cancer Incidence ◽

Screening Programme ◽

Tumour Size ◽

Breast Cancer Mortality ◽

Breast Cancer Incidence ◽

Large Tumour ◽

Large Breast ◽

Large Tumour Size

Objective A decrease in advanced breast cancer incidence is considered an early indicator of breast cancer mortality reduction in a screening programme. We describe trends in breast cancer incidence according to tumour size and age in three French administrative areas, where an organized screening programme was implemented during the 1990s. Methods Our study included all 28,092 invasive breast cancers diagnosed from 2000 to 2010 in women living in three areas (Hérault, Isère, Loire-Atlantique). Age, year of diagnosis, and size of tumour at diagnosis was provided by the three area cancer registries. Poisson regression models were fitted to estimate changes in incidence over time, after adjustment for age and administrative area. Results From 2000 to 2010, the incidence rate of large (tumour size >20 mm) breast cancer linearly decreased in women aged 50–74 (target age of the screening programme) from 108.4 to 84.1/100,000 (annual percent change = −1.9%, p < 0.001). No change in large breast cancer incidence rate was found in women aged 20–49, or older than 74. Conclusions A decreasing trend in incidence of large tumour size breast cancer in the target age of the screening programme is demonstrated for the first time in France. The overall 20.9% linear decrease over 11 years in these three areas is encouraging and should be closely monitored and extended to other areas of France, where the screening programme was generally implemented only in 2004.

Download Full-text